Bridgebio Pharma Inc
(BBIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 642,951 | 748,953 | 540,599 | 681,101 | 405,733 |
| Marketable Securities | 2,991 | 7,939 | N/A | N/A | N/A |
| Receivables | 116,518 | 76,868 | 115,265 | 4,722 | 478 |
| Inventories | 24,527 | 18,277 | 3,954 | 0 | N/A |
| TOTAL | $839,382 | $912,277 | $695,173 | $720,692 | $444,578 |
| Non-Current Assets | |||||
| PPE Net | 5,830 | 6,107 | 6,698 | 7,011 | 8,701 |
| Investments And Advances | 92,168 | 108,002 | 128,191 | 143,747 | 160,443 |
| Intangibles | 28,795 | 29,513 | 27,802 | 23,926 | 24,525 |
| Other Non-Current Assets | 32,075 | 24,291 | 23,774 | 23,962 | 26,730 |
| TOTAL | $158,868 | $167,913 | $186,465 | $198,646 | $220,399 |
| Total Assets | $998,250 | $1,080,190 | $881,638 | $919,338 | $664,977 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 18,702 | 26,134 | 27,525 | 9,618 | 13,363 |
| Accrued Expenses | 90,774 | 68,482 | 67,077 | 92,601 | 109,482 |
| Other current liabilities | 92,743 | 65,916 | 40,674 | 33,071 | N/A |
| TOTAL | $216,600 | $175,854 | $152,105 | $154,400 | $139,216 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,851,016 | 1,849,559 | 1,848,124 | 1,721,382 | 1,719,316 |
| Deferred Revenues | 9,087 | 10,540 | 11,620 | 14,604 | 11,771 |
| Other Non-Current Liabilities | 842,449 | 819,939 | 504,525 | 486,554 | 9,069 |
| TOTAL | $2,704,402 | $2,682,310 | $2,367,971 | $2,222,692 | $1,744,798 |
| Total Liabilities | $2,921,002 | $2,858,164 | $2,520,076 | $2,377,092 | $1,884,014 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 192,709 | 191,169 | 189,881 | 190,189 | 188,990 |
| Common Shares | 200 | 198 | 197 | 196 | 195 |
| Retained earnings | -3,628,331 | -3,445,588 | -3,263,685 | -3,096,263 | -2,831,213 |
| Other shareholders' equity | 10,044 | 9,611 | 9,681 | 10,158 | 10,890 |
| TOTAL | $-1,922,752 | $-1,777,974 | $-1,638,438 | $-1,457,754 | $-1,219,037 |
| Total Liabilities And Equity | $998,250 | $1,080,190 | $881,638 | $919,338 | $664,977 |